Microbix Biosystems supports the FTC's proposed study of generic drug competition
MLex Summary: Microbix Biosystems supports the US Federal Trade Commission's proposed study of generic drug competition saying that it is imperative that the FTC investigate violations of the Hatch-Waxman Act. Microbix...To view the full article, register now.
Already a subscriber? Click here to view full article